#United States #San Diego #Robbins LLP #Replimune Group #RP1

Replimune Group Inc. Class Action Lawsuit

Robbins LLP, a firm dedicated to protecting shareholder rights, has announced that a class action lawsuit has been initiated on behalf of all individuals and entities who acquired securities from Replimune Group, Inc. (NASDAQ: REPL). This class action seeks justice for those who purchased or otherwise obtained shares during the period spanning from October 20, 2025, to April 10, 2026, commonly referred to as the "Class Period."

Replimune is identified as a clinical-stage biotechnology company, primarily focused on innovative immunotherapies designed to combat cancer. The firm’s flagship product candidate, RP1 (vusolimogene oderparepvec), has been central to their operations and promises.

The legal complaint claims that Replimune misrepresented vital facts concerning the effectiveness and viability of RP1. It suggests that the company misled shareholders about the product’s clinical trial outcomes and the FDA's responsiveness to the Biologics License Application (BLA) associated with RP1.

Key Allegations

On October 20, 2025, Replimune publicized that the U.S. Food and Drug Administration (FDA) had accepted its resubmission for the BLA concerning RP1, in conjunction with nivolumab, aimed at treating advanced melanoma in patients not responding to anti-PD-1 therapy. The company further claimed that it furnished additional information and data in this resubmission, positioning the development positively.

However, the lawsuit argues that the company failed to disclose critical issues regarding its BLA related to the study design concerns repeatedly highlighted by the FDA, indicating that these significant issues were left unaddressed. It also alleges that the data provided by Replimune was derived from an early and unplanned analysis involving merely 40 patients, constituting only 10% of the anticipated sample size of 400.

Other claims include that both the RP1-104 study and RPL-001-16 trials had notable deficiencies, which likely jeopardized the FDA’s approval of the BLA.

On April 10, 2026, the FDA rejected the BLA, citing multiple deficiencies in the submitted studies. Reports indicate that the marketing communication from Replimune created an illusion of assurance regarding the BLA's acceptance, leading shareholders to believe that their investments were secure despite lingering uncertainties.

Impact on Shareholder Value

Following the adverse FDA decision, Replimune’s stock price plummeted, falling by $1.15 (19.46%) on April 10, 2026. Trading was halted due to abnormal market behaviors. The downward trend continued after Replimune’s statement subsequently acknowledged the FDA's preference for randomized controlled trials, driving the share price down further to close at $1.70 per share on April 13, 2026.

Who Can Join the Class Action?

Investors who experienced losses stemming from their investments in REPL securities during the designated class period may possess rights under federal securities laws to participate in this class action lawsuit. If you acquired Replimune shares during this window and faced financial losses, it could be beneficial to take action.

No Upfront Costs

Robbins LLP facilitates representation on a contingency fee basis; thus, investors will incur no legal fees or litigation expenses unless a recovery is obtained. If there are financial recuperations for shareholders, Robbins LLP will receive compensation directly from the defendants.

About Robbins LLP

As a pivotal entity in the field of shareholder rights litigation, Robbins LLP has managed to reclaim over $1 billion for investors, celebrated significant recoveries, and prompted corporate governance reforms across more than 400 Fortune 1000 companies. The firm embraces a mission of accountability, transparency, and equitable governance among organizations.

For additional insight regarding the Replimune Group class action, interested parties can contact Robbins LLP for further information, submit inquiries through their website, or reach attorney Aaron Dumas, Jr. at (800) 350-6003.